NASDAQ:OMER

Omeros Falls 4.3% After Hours Despite YARTEMLEA Revenue Growth

Omeros (NASDAQ: OMER) shares fell 4.3% in after-hours trading even as YARTEMLEA continued to post sequential revenue growth in the third quarter.

YARTEMLEA gross revenue rose 30% sequentially to $41.8 million, while net revenue increased 26% to $35.9 million. Excluding non-cash derivative adjustments, adjusted net income improved to $4.7 million, or $0.06 per share, from $1.8 million in the prior quarter.

However, GAAP results swung to a $57.4 million net loss, largely because of a $62.0 million non-cash mark-to-market loss tied to convertible notes. The company also disclosed that the EMA’s CHMP issued a negative opinion on narsoplimab’s European marketing application after re-examination.

The after-hours decline appears to reflect investor concern around the European regulatory setback and headline GAAP loss, despite continued YARTEMLEA growth and positive operating cash flow.